AKT1 and renal cell carcinoma: Furthermore, the overactivation of AXL and c-MET is known to activate the STAT3, AKT, and ERK signaling pathways, which are also activated by the AKT signaling pathway that upregulates lncARSR in drug-resistant RCC cells.